Net income
-28.8 million USD
2022-01-01 – 2022-12-31
Fundies. English
Axovant Gene Therapies Ltd.
EDGAR150 filing records in this dataset, filed from 2015-05-11 to 2023-02-14. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 46.1 million USD Source
Exact value
46100000 USD
- Long-term debt including current maturities
- 15.4 million USD Source
Exact value
15400000 USD
- Shares outstanding
- 74 million shares Source
Exact value
73975196 shares
Reported share-count change
0.38% · 278 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-36.5 million USD
2022-01-01 – 2022-12-31
Exact inputs and evidence
- Operating cash flow: -60346000 USD · 2021-04-01 – 2022-03-31 Source
- Operating cash flow: -42524000 USD · 2021-04-01 – 2021-12-31 Source
- Operating cash flow: -8681000 USD · 2022-04-01 – 2022-06-30 Source
- Operating cash flow: -13764000 USD · 2022-04-01 – 2022-09-30 Source
- Operating cash flow: -8681000 USD · 2022-04-01 – 2022-06-30 Source
- Operating cash flow: -18686000 USD · 2022-04-01 – 2022-12-31 Source
- Operating cash flow: -13764000 USD · 2022-04-01 – 2022-09-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2023-02-14.
Financial data available through: 2022-03-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 7 of 11 periods available· newest 2022-03-31
- Net income: 7 of 11 periods available· newest 2022-03-31
- Operating cash flow: 7 of 11 periods available· newest 2022-03-31
- capital expenditure: No compatible figures in this window
- Total assets: 7 of 11 periods available· newest 2022-03-31
- Total liabilities: 7 of 11 periods available· newest 2022-03-31
- Current assets: 7 of 11 periods available· newest 2022-03-31
- Current liabilities: 7 of 11 periods available· newest 2022-03-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2022-03-31
- Long-term debt including current maturities: 4 of 11 periods available· newest 2020-03-31
- Shares outstanding: 7 of 11 periods available· newest 2022-03-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 39.5 millionPrior period
−USD 32.4 million
–
Current period
−USD 71.9 million
–
Exact inputs and evidence
-71900000 − -32400000 = -39500000 USD
-32400000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source-71900000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 13.76 millionPrior period
−USD 46.59 million
–
Current period
−USD 60.35 million
–
Exact inputs and evidence
-60346000 − -46589000 = -13757000 USD
-46589000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source-60346000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2015-04-01 – 2016-03-31 | −USD 133.15 million Exact valueExact value: -133145000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.35 million Exact valueExact value: -53347000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2016-04-01 – 2017-03-31 | −USD 180.95 million Exact valueExact value: -180951000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 112.11 million Exact valueExact value: -112109000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2017-04-01 – 2018-03-31 | −USD 221.6 million Exact valueExact value: -221600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 190.35 million Exact valueExact value: -190348000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-04-01 – 2019-03-31 | −USD 129.1 million Exact valueExact value: -129100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 134.21 million Exact valueExact value: -134207000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-04-01 – 2020-03-31 | −USD 72.6 million Exact valueExact value: -72600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 67.47 million Exact valueExact value: -67473000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2020-04-01 – 2021-03-31 | −USD 32.4 million Exact valueExact value: -32400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 46.59 million Exact valueExact value: -46589000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2021-04-01 – 2022-03-31 | −USD 71.9 million Exact valueExact value: -71900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 60.35 million Exact valueExact value: -60346000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
150 filings · 1,696 latest values · 1,696 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001636050, 1636050, AXGT, SIOX, edgar:1636050
Also known as Axovant Gene Therapies Ltd., Axovant Sciences Ltd., Roivant Neurosciences Ltd., Sio Gene Therapies Inc.